Zhuhai Rundu Pharmaceutical (002923.SZ) has received marketing approval for Mosapride Citrate API.
Rundu Pharmaceutical (002923.SZ) announced that the company recently received the "Chemical API Marketing Application Approval Notification" for Mosapride Citrate issued by the National Medical Products Administration. The receipt of this marketing approval notification for Mosapride Citrate API further improves the company's product layout in the digestive field, enriches its product matrix, helps enhance overall market competitiveness, and aligns with the company's development strategy.
Zhuhai Rundu Pharmaceutical (002923.SZ) announced that the company recently received the "Chemical API Marketing Application Approval Notification" for Mosapride Citrate issued by the National Medical Products Administration. The receipt of this marketing approval notification for Mosapride Citrate API further improves the company's product layout in the digestive field, enriches its product matrix, helps enhance overall market competitiveness, and aligns with the company's development strategy.
Related Articles
CGN NEW ENERGY (01811) repurchased 336,000 shares for HK$703,900 on October 13.
CH INNOVATION (01217) net asset value per share at the end of September was approximately HK$0.043.
KWG GROUP (01813) September pre-sales amounted to RMB 200 million, a year-on-year decrease of 73.2%.
CGN NEW ENERGY (01811) repurchased 336,000 shares for HK$703,900 on October 13.
CH INNOVATION (01217) net asset value per share at the end of September was approximately HK$0.043.
KWG GROUP (01813) September pre-sales amounted to RMB 200 million, a year-on-year decrease of 73.2%.
